Literature DB >> 19735656

Trypanosoma cruzi: In vitro effect of aspirin with nifurtimox and benznidazole.

Rodrigo López-Muñoz1, Mario Faúndez, Sebastián Klein, Sebastián Escanilla, Gloria Torres, Dasfne Lee-Liu, Jorge Ferreira, Ulrike Kemmerling, Myriam Orellana, Antonio Morello, Arturo Ferreira, Juan D Maya.   

Abstract

Nifurtimox and benznidazole are the only active drugs against Trypanosoma cruzi; however, they have limited efficacy and severe side effects. During primoinfection, T. cruzi infected macrophages mount an antiparasitic response, which the parasite evades through an increase of tumor growth factor beta and PGE(2) activation as well as decreased iNOS activity. Thus, prostaglandin synthesis inhibition with aspirin might increase macrophage antiparasitic activity and increase nifurtimox and benznidazole effect. Aspirin alone demonstrated a low effect upon macrophage antiparasitic activity. However, isobolographic analysis of the combined effects of aspirin, nifurtimox and benznidazole indicated a synergistic effect on T. cruzi infection of RAW cells, with combinatory indexes of 0.71 and 0.61, respectively. The observed effect of aspirin upon T. cruzi infection was not related with the PGE(2) synthesis inhibition. Nevertheless, NO() levels were restored by aspirin in T. cruzi-infected RAW cells, contributing to macrophage antiparasitic activity improvement. Thus, the synergy of aspirin with nifurtimox and benznidazole is due to the capability of aspirin to increase antiparasitic activity of macrophages. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735656     DOI: 10.1016/j.exppara.2009.09.005

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  14 in total

1.  Synergistic effect of inhibitors of fatty acid desaturases on Trypanosoma parasites.

Authors:  Andrés Alloatti; Karina E J Tripodi; Antonio D Uttaro
Journal:  Parasitol Res       Date:  2013-06-25       Impact factor: 2.289

2.  Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.

Authors:  Aparecida D Malvezi; Carolina Panis; Rosiane V da Silva; Rafael Carvalho de Freitas; Maria I Lovo-Martins; Vera L H Tatakihara; Nágela G Zanluqui; Edecio Cunha Neto; Samuel Goldenberg; Juliano Bordignon; Sueli F Yamada-Ogatta; Marli C Martins-Pinge; Rubens Cecchini; Phileno Pinge-Filho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

3.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

4.  Simvastatin and Benznidazole-Mediated Prevention of Trypanosoma cruzi-Induced Endothelial Activation: Role of 15-epi-lipoxin A4 in the Action of Simvastatin.

Authors:  Carolina Campos-Estrada; Ana Liempi; Fabiola González-Herrera; Michel Lapier; Ulrike Kemmerling; Barbara Pesce; Jorge Ferreira; Rodrigo López-Muñoz; Juan D Maya
Journal:  PLoS Negl Trop Dis       Date:  2015-05-15

5.  Aspirin modulates innate inflammatory response and inhibits the entry of Trypanosoma cruzi in mouse peritoneal macrophages.

Authors:  Aparecida Donizette Malvezi; Rosiane Valeriano da Silva; Carolina Panis; Lucy Megumi Yamauchi; Maria Isabel Lovo-Martins; Nagela Ghabdan Zanluqui; Vera Lúcia Hideko Tatakihara; Luiz Vicente Rizzo; Waldiceu A Verri; Marli Cardoso Martins-Pinge; Sueli Fumie Yamada-Ogatta; Phileno Pinge-Filho
Journal:  Mediators Inflamm       Date:  2014-06-19       Impact factor: 4.711

6.  Effects of (1E,4E)-2-Methyl-1,5-bis(4-nitrophenyl)penta-1,4-dien-3-one on Trypanosoma cruzi and Its Combinational Effect with Benznidazole, Ketoconazole, or Fluconazole.

Authors:  Francieli Peron; Danielle Lazarin-Bidóia; Zia Ud Din; Edson Rodrigues-Filho; Tânia Ueda-Nakamura; Sueli de Oliveira Silva; Celso Vataru Nakamura
Journal:  Biomed Res Int       Date:  2017-05-23       Impact factor: 3.411

7.  Protective role of acetylsalicylic acid in experimental Trypanosoma cruzi infection: evidence of a 15-epi-lipoxin A₄-mediated effect.

Authors:  Alfredo Molina-Berríos; Carolina Campos-Estrada; Natalia Henriquez; Mario Faúndez; Gloria Torres; Christian Castillo; Sebastián Escanilla; Ulrike Kemmerling; Antonio Morello; Rodrigo A López-Muñoz; Juan D Maya
Journal:  PLoS Negl Trop Dis       Date:  2013-04-18

8.  Synergistic Effect of Lupenone and Caryophyllene Oxide against Trypanosoma cruzi.

Authors:  Glendy Polanco-Hernández; Fabiola Escalante-Erosa; Karlina García-Sosa; María E Rosado; Eugenia Guzmán-Marín; Karla Y Acosta-Viana; Alberto Giménez-Turba; Efraín Salamanca; Luis M Peña-Rodríguez
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-20       Impact factor: 2.629

Review 9.  Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase.

Authors:  Hugo Cerecetto; Mercedes González
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-25

10.  Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment.

Authors:  Elena Aguilera; Javier Varela; Elva Serna; Susana Torres; Gloria Yaluff; Ninfa Vera de Bilbao; Hugo Cerecetto; Guzmán Alvarez; Mercedes González
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-03       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.